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Conclusion: The most common genotype was 1a that it
was accordant to studies that conducted in general popula-
tion in Iran.
doi:10.1016/j.ijid.2008.05.1255
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Background: Chronic infection of hepatitis C virus (HCV)
may lead to hepatic ﬁbrosis and the precise mechanisms
remain unclear. Our previous study indicated that E2 protein
may involve in the hepatic ﬁbrogenesis via an up-regulation
of ﬁbrosis-related proteins.
Methods: To further conﬁrm this ﬁnding, E2 gene silenc-
ing and a treatment with silibinin was conducted on
E2-expressing cells and RT-PCR analysis was performed.
Results: E2-enhanced expression of ﬁbrosis-related
molecules, including alpha-SMA, collagen alpha(I), TGF-1,
connective tissue growth factor (CTGF), IL-6 and IL-1, MMP-
2, were all abolished by a treatment with siRNA speciﬁc
for E2. Furthermore, a treatment with silibinin, a potent
antioxidant, was conducted to gain similar results.
Conclusion: These results further prove that E2 protein
may involve in the process of hepatic ﬁbrogenesis and E2-
related ﬁbrosis may be, at least in part, through an oxidative
damage-related pathway.
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Introduction: Impaired natural killer (NK) cell activity
contributes to viral persistence in HCV infection. Recent
studies demonstrated that in tumors regulatory T cells (Treg)
- via secreting TGF-beta1 - down-regulate NKG2D killer
activator receptor and are responsible for poor NK cytox-
icity. Since in chronic hepatitis C plasma TGF-beta1 level is
increased, we analyzed the expression of NKG2D on NK and
T cells and its correlation with the percentage of Treg cells
and TGF-beta1 levels.
Methods: The peripheral CD4+CD25high+ Treg cells,
NKG2D+ NK and T cells were determined by FACS, plasma
TGF-beta1 levels by ELISA. Forty three patients with active
chronic hepatitis C, 10 sustained virological responders
(SVR) and 15 healthy controls were enrolled.
Results: In patients with chronic hepatitis C the NKG2D
expression was down-regulated both on NK (7,9 vs. 20,9%)
and T cells (18 vs. 26,3%) compared to controls. Impaired
expression of NKG2D was associated with increased pro-
portion of CD4+CD25high+ Treg cells (4,6 vs. 3,1%) and
increased TGF-beta1 levels (15 vs.9 pg/ml) compared to con-
trols. TGF-beta1 inversely correlated with NKG2D expression
on NK cells. In SVR group, the percentage of Treg cells
(1,7± 0,2%), TGF-beta1 levels (11,6 pg/ml) and NKG2D
expression (NK:17%, T:20,9%) were comparable to controls.
Discussion/Conclusion: Our data suggest that TGF-beta1
- secreted by regulatory T cells - may be responsible for
impaired NK cell function via down-regulating NKG2D. Thus,
TGF-beta1 antagonism or soluble NKG2D ligands may provide
the basis of a novel immunotherapy to improve the function
of NK and T cells in chronic hepatitis C.
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Objective: A nation-wide retrospective analysis has been
performed in order to assess the efﬁcacy of antiviral therapy
for patients with chronic hepatitis B and C representing the
entire population that needed treatment in Hungary, during
a seven-year period. In addition, results of a prospective
study including patients with chronic hepatitis C are also
presented.
Patients and Methods: Of 220 patients with hepatitis
B, 112 were treated with standard interferon-alpha (IFN),
23 with pegylated interferon-alpha-2a (PEG-IFN) and 85
with lamivudine (LAM), and the ratio of HBeAg seroconver-
sion and/or undetectable HBV-DNA has been assessed. Of
2442 patients with hepatitis C, 333 were treated with IFN
monotherapy, 1122 with IFN + ribavirin (RBV) and 987 with
PEG-IFN + RBV for 6—12 months. In the prospective study, 69
patients with chronic hepatitis C were enrolled and treated
with PEG-IFN alfa-2a + RBV. The rate of sustained virological
response (SV), the predictors of outcome and the adverse
effects of treatment were evaluated.
Results: For HBV patients IFN, PEG-IFN and LAM provided
31, 30, and 33% SVR rate, respectively. In chronic hepatitis C,
